BackYield10 Bioscience Overview

Yield10 Bioscience Common Stock

Track Yield10 Bioscience's common stock ($6K) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Common Stock
$6000.00
90.16% YoYΔ $-55000.00 vs prior year quarter

Peer trimmed avg / median

Loading

Yield10 Bioscience Common Stock History

Loading

Yield10 Bioscience vs. peers: Common Stock Comparison

Loading

Yield10 Bioscience Common Stock Growth (YoY per quarter)

Latest change versus the prior comparable period (same company). Positive growth indicates new issuance/dilution; negative growth indicates reductions/buybacks.

Loading

Yield10 Bioscience (YTEN) FAQ

Yield10 Bioscience's common stock stands at $6K as of June 2024. That compares with $61K in the prior-year period — down 90.2% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Yield10 Bioscience reported $6K in common stock versus $61K a year earlier — a 90.2% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $61K in the prior-year period — down 90.2% year over year. Sustained growth in common stock can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Yield10 Bioscience's common stock evolved across reporting periods, while the comparison chart places YTEN next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Consumer Discretionary, common stock is commonly used to spot outliers. Yield10 Bioscience's reading of $6K is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.